Prospects for Liquid Biopsy Using MicroRNA and Extracellular Vesicles in Breast Cancer

Overview

Journal Breast Cancer

Specialty Oncology

Date 2024 Mar 30

PMID 38554234

Authors

Takahiro Ochiya

Kazuki Hashimoto

Akihiko Shimomura

Affiliations

Soon will be listed here.

Abstract

Among the analytes circulating in body fluids, microRNAs, a type of non-coding RNA and known to exist 2655 in primates, have attracted attention as a novel biomarker for cancer screening. MicroRNAs are signaling molecules with important gene expression regulatory functions that can simultaneously control many gene functions and multiple different pathways in living organisms. These microRNAs are transported in extracellular vesicles (EVs), which are lipid bilayers with 50-150 nm in diameter, and are used as communication tools between cells. Furthermore, the EVs that carry these microRNAs circulate in the bloodstream and have other important implications for understanding the pathogenesis and diagnosis of breast cancer. The greatest benefit from cancer screening is the reduction in breast cancer mortality rate through early detection. Other benefits include reduced incidence of breast cancer, improved quality of life, prognosis prediction, contribution to personalized medicine, and relative healthcare cost containment. This paper outlines the latest developments in liquid biopsy for breast cancer, especially focusing on microRNA and EV diagnostics.

References

Machii R, Takahashi H . Japanese cancer screening programs during the COVID-19 pandemic: Changes in participation between 2017-2020. Cancer Epidemiol. 2022; 82:102313. PMC: 9726684. DOI: 10.1016/j.canep.2022.102313. View

Srivastava S, Koay E, Borowsky A, De Marzo A, Ghosh S, Wagner P . Cancer overdiagnosis: a biological challenge and clinical dilemma. Nat Rev Cancer. 2019; 19(6):349-358. PMC: 8819710. DOI: 10.1038/s41568-019-0142-8. View

Xie W, Suryaprakash S, Wu C, Rodriguez A, Fraterman S . Trends in the use of liquid biopsy in oncology. Nat Rev Drug Discov. 2023; 22(8):612-613. DOI: 10.1038/d41573-023-00111-y. View

Matsuzaki J, Ochiya T . Circulating microRNAs: Next-generation Cancer Detection. Keio J Med. 2020; 69(4):88-96. DOI: 10.2302/kjm.2019-0011-OA. View

Matsuzaki J, Kato K, Oono K, Tsuchiya N, Sudo K, Shimomura A . Prediction of tissue-of-origin of early stage cancers using serum miRNomes. JNCI Cancer Spectr. 2022; 7(1). PMC: 9825310. DOI: 10.1093/jncics/pkac080. View

Yoshioka Y, Konishi Y, Kosaka N, Katsuda T, Kato T, Ochiya T . Comparative marker analysis of extracellular vesicles in different human cancer types. J Extracell Vesicles. 2013; 2. PMC: 3760642. DOI: 10.3402/jev.v2i0.20424. View

Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J . Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci. 2016; 107(3):326-34. PMC: 4814263. DOI: 10.1111/cas.12880. View

Shiino S, Matsuzaki J, Shimomura A, Kawauchi J, Takizawa S, Sakamoto H . Serum miRNA-based Prediction of Axillary Lymph Node Metastasis in Breast Cancer. Clin Cancer Res. 2018; 25(6):1817-1827. DOI: 10.1158/1078-0432.CCR-18-1414. View

Sato J, Shimomura A, Kawauchi J, Matsuzaki J, Yamamoto Y, Takizawa S . Brain metastasis-related microRNAs in patients with advanced breast cancer. PLoS One. 2019; 14(10):e0221538. PMC: 6788729. DOI: 10.1371/journal.pone.0221538. View

Satomi-Tsushita N, Shimomura A, Matsuzaki J, Yamamoto Y, Kawauchi J, Takizawa S . Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer. PLoS One. 2019; 14(9):e0222024. PMC: 6726239. DOI: 10.1371/journal.pone.0222024. View

10.

Noda-Narita S, Shimomura A, Tanabe Y, Kawauchi J, Matsuzaki J, Takizawa S . Peripheral neuropathy from paclitaxel: risk prediction by serum microRNAs. BMJ Support Palliat Care. 2020; . PMC: 11671922. DOI: 10.1136/bmjspcare-2019-001900. View

11.

Li B, Lu Y, Yu L, Han X, Wang H, Mao J . Corrigendum to "miR-221/222 promote cancer stem-like cell properties and tumor growth of breast cancer via targeting PTEN and sustained Akt/NF-κB/COX-2 activation" [Chem. Biol. Interact. 277 (2017) 33-42]. Chem Biol Interact. 2021; 345:109556. DOI: 10.1016/j.cbi.2021.109556. View

11.

Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee J, Lotvall J . Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9(6):654-9. DOI: 10.1038/ncb1596. View

12.

Kosaka N, Yoshioka Y, Fujita Y, Ochiya T . Versatile roles of extracellular vesicles in cancer. J Clin Invest. 2016; 126(4):1163-72. PMC: 4811151. DOI: 10.1172/JCI81130. View

13.

Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T . Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010; 285(23):17442-52. PMC: 2878508. DOI: 10.1074/jbc.M110.107821. View

14.

Villarroya-Beltri C, Baixauli F, Gutierrez-Vazquez C, Sanchez-Madrid F, Mittelbrunn M . Sorting it out: regulation of exosome loading. Semin Cancer Biol. 2014; 28:3-13. PMC: 4640178. DOI: 10.1016/j.semcancer.2014.04.009. View

15.

Kawamura Y, Yamamoto Y, Sato T, Ochiya T . Extracellular vesicles as trans-genomic agents: Emerging roles in disease and evolution. Cancer Sci. 2017; 108(5):824-830. PMC: 5448650. DOI: 10.1111/cas.13222. View

16.

Liu Q, Peng F, Chen J . The Role of Exosomal MicroRNAs in the Tumor Microenvironment of Breast Cancer. Int J Mol Sci. 2019; 20(16). PMC: 6719057. DOI: 10.3390/ijms20163884. View

17.

Tominaga N, Kosaka N, Ono M, Katsuda T, Yoshioka Y, Tamura K . Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat Commun. 2015; 6:6716. PMC: 4396394. DOI: 10.1038/ncomms7716. View

18.

Gu P, Sun M, Li L, Yang Y, Jiang Z, Ge Y . Breast Tumor-Derived Exosomal MicroRNA-200b-3p Promotes Specific Organ Metastasis Through Regulating CCL2 Expression in Lung Epithelial Cells. Front Cell Dev Biol. 2021; 9:657158. PMC: 8264457. DOI: 10.3389/fcell.2021.657158. View